[{"id":"8fd2786b-62b1-42fe-adb7-71fd80110fe8","acronym":"","url":"https://clinicaltrials.gov/study/NCT03808480","created_at":"2021-01-18T18:49:12.518Z","updated_at":"2024-07-02T16:36:13.876Z","phase":"Phase 2","brief_title":"Nivolumab After Cyclophosphamide and Doxorubicin Induction Therapy in NSCLC With PD-L1","source_id_and_acronym":"NCT03808480","lead_sponsor":"National Cancer Center, Korea","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • doxorubicin hydrochloride • cyclophosphamide • L1-10 • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 22","initiation":"Initiation: 01/23/2019","start_date":" 01/23/2019","primary_txt":" Primary completion: 05/31/2022","primary_completion_date":" 05/31/2022","study_txt":" Completion: 05/31/2022","study_completion_date":" 05/31/2022","last_update_posted":"2022-04-06"}]